Bicara Therapeutics 주식 (NASDAQ: BCAX)

에 대한 최신 뉴스 Bicara Therapeutics (NASDAQ:BCAX) 주식

Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

버서스 시스템즈(NASDAQ:VS)의 주가는 회사가 국제적인 입지를 성장시키기 위한 전략의 일환으로 회사가 브라질 시장으로의 확장을 발표한 후 급등했다. 버서스 시스템즈의 주가가 금요일 프리마켓 거래에서 71.2% 상승하여 $3.39에 거래되었다.

버서스 시스템즈 주식이 약 71% 상승한 이유: 프리마켓에서 움직이는 20개의 주식

Bicara Therapeutics Inc

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea's official patent and intellectual property authority. The patent covers the Company's innovative combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction.
The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These studies build upon earlier experiments in which animals treated with MEAI exhibited a significant reduction in cocaine-induced cravings.
Further research was conducted in rats to assess whether MEAI's effects on drug-seeking behavior extended to natural rewards, given that reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats' response to natural rewards such as sucrose. This finding suggests that MEAI's impact on drug cravings is not tied to the general reward system but is specifically targeted at drug-related compulsions.
This pioneering research has led to multiple patent applications in the U.S. and other global jurisdictions and is part of Clearmind's ongoing collaboration with SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) ("SciSparc"), a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders. The collaboration aims to combine Clearmind's MEAI, a novel proprietary psychedelic treatment for addiction and mental health, with SciSparc's PEA

Government

Regulations

CMND

SPRC

Clearmind Wins South Korea Patent for Psychedelic Therapy Targeting Cocaine Addiction

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10080426/Cango-0310-01.jpeg" alt="" class="wp-image-7456" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10080426/Cango-0310-01.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10080426/Cango-0310-01-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10080426/Cango-0310-01-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The company, whose main business was previously auto trading, said its revenue skyrocketed in the fourth quarter after its move into bitcoin mining
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Cango's revenue rose more than fivefold to 668 million yuan in last year's fourth quarter, following its launch of a bitcoin mining operation last November</li>
<li>The company will add 18 EH of new capacity by the end of this quarter, bringing its total to 50 EH, making it the world's second-largest bitcoin miner</li>
</ul>
There's nothing like a new business model to put some new spring into your step.
After watching its revenue dwindle for a year and a half,&nbsp;Cango Inc.&nbsp;(CANG.US) came roaring back in the final quarter of last year, following a major shift into the cryptocurrency mining business in November. This was no subtle shift either. The company's revenue skyrocketed by more than a factor of five to 668 million yuan ($92 million) for the quarter from 130.2 million yuan a year earlier.
The latest figure not only marked Cango's first year-on-year revenue growth since the second quarter of 2023, but was also its highest total since that quarter. And in one final impressive feat, the figure was light years ahead of the company's forecast just three months earlier for fourth-quarter revenue of just 15 million yuan to 17.5 million yuan – quite possibly the biggest revenue "beat" of all time for any company.
The crypto shift looks set to continue for Cango, which announced a major expansion to its mining capacity in the current quarter and the potential for more in the second half of the year. The company is also aware of the risks of tying its fate to such a volatile sector, and broadly discussed some of the steps it is taking to control such risk. As a newcomer to the industry, Cango is also still on a sharp learning curve, which is reflected in its relatively high costs for each bitcoin it mines compared with some older peers. Those higher costs also owe to Cango's asset-light business model that differs from many of its peers by requiring much lower up-front investment, but with higher operating costs.
The sudden revenue jolt owes completely to Cango's move into cryptocurrency in November. Before that, the company was engaged in the auto business, first as a car loan financier, and more recently as a provider of domestic and international car trading services. That was fine when China's car industry was booming for most of the 21st&nbsp;century, as it zipped past the U.S. to become the world's largest market.
But the market has become stuck in slow-growth mode over the last few years as China's economy slows, resulting in huge overcapacity built up over the boom years. That's led to endless price wars with most companies losing money, leading Cango to scale down its car business to avoid falling into the same trap.
Reaction to Cango's latest report after its release last Thursday was relatively muted, with its shares rising 2.1% the next day. The stock has doubled over the last six months since Cango first announced the move into crypto mining in early November. But notably, the shares are also down 28% so far this year, tracking an 8% drop for bitcoin, showing the company's future will inevitably follow bitcoin prices to some extent.
Reflecting its newness to the industry, Cango's shares currently trade at a relatively low forward price-to-earnings (P/E) ratio of between 4 and 8, based on our calculations using its likely profit for this year derived from its fourth-quarter performance. That's well behind the ratio of 40 for industry leader&nbsp;Mara&nbsp;(MARA.US). Better comparisons might be&nbsp;Cipher&nbsp;(CIFR.US) and&nbsp;Bitfufu&nbsp;(FUFU.US), which trade higher than Cango with P/E ratios of 12, implying Cango's stock could still have some upside as more investors discover the company.
<h4 class="wp-block-heading">High mining costs</h4>
Cango first announced its plans to purchase $400 million worth of mining machines in November, and completed the first tranche of that the same month with its acquisition of $250 million worth. The company currently operates more than 138,000 machines in the U.S., East Africa, Oman, Paraguay and Canada, with the U.S. hosting about 40% of its capacity.
That operation began mining in mid-November, minting 363.9 bitcoins that month and another 569.9 in December. It minted another 538.2 bitcoins in January and 472.2 in February. Over that period, its production fell from 18.4 bitcoins mined each day in December to 16.9 in February, reflecting the growing competition for new bitcoins that are created at a constant rate by an algorithm no matter how many people are engaged in mining.
The company's output should soon get a one-time boost, as Cango disclosed it expects to complete its acquisition of the remaining $150 million worth of mining machines by the end of this month. CEO Lin Jiayuan said Cango will focus on installing and operating that capacity in the first half of this year, and also improving its efficiency.
The company said its cost for mining each bitcoin, excluding depreciation of its mining machines, was $67,769.90 in the fourth quarter. While that's below the current industry average of about $86,000, according to the website MacroMicro, it's still quite a bit higher than Mara's $51,035 in its latest financial report. Cango noted that the new installations will raise its capacity from the current 32 exahashes (EH) to 50 EH, making it the world's second-biggest listed miner behind only Mara.
An important reason for its higher cost-per-bitcoin mined is Cango's capital-light business model, whereby it installs its machines at existing facilities built by others. By comparison, Mara and many others build their own mining facilities, requiring far more capital but significantly lowering electricity costs that are one of their biggest expenses. Cango also has lower depreciation costs through its use of second-hand mining machines, unlike others like Mara, which use new machines.
"In the second half (of 2025), we will pursue a hash rate expansion strategy, actively seeking valuable assets to increase our overall capacity," Lin said on Cango's investor call, suggesting that even more expansion could be coming.
In terms of operating costs, the rapid bitcoin business buildup was most evident in Cango's general and administrative expenses, which nearly tripled to 127.9 million yuan in the fourth quarter from 45.6 million yuan a year earlier. But the huge jump in revenue was more than enough to offset that, with the company reporting a 55.9 million yuan profit, reversing a 103.8 million yuan loss a year earlier.
Cango also commented on its older auto businesses, including its progress in winding down its original auto financing business. It also disclosed that its newest international business expected to make its first sales of about $15 million this year through the export 1,500 cars.
The company also discussed some of the steps it is taking to control risk related to price fluctuations, including its establishment of a "comprehensive market monitoring protocol and a robust policy analysis mechanism." On the regulatory front, one of the company's most immediate risks could be its base in China, where cryptocurrency is officially banned, even though all Cango's mining operations are outside the country. In that regard, it could ultimately follow many of its formerly Chinese peers by moving its headquarters overseas, with Singapore as one of the most popular destinations for such relocations.

Asia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Cango's Fortunes Turn Around Following Move Into Bitcoin Mining

Citigroup analyst Jason Gursky initiates coverage on Karman Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) with a Buy rating and announces Price Target of $42.

Price Target

Initiation

Analyst Ratings

KRMN

Citigroup Initiates Coverage On Karman Holdings with Buy Rating, Announces Price Target of $42

Citigroup analyst Ariel Rosa upgrades Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) from Sell to Neutral and announces $53 price target.

Upgrades

Citigroup Upgrades Knight-Swift to Neutral, Announces $53 Price Target

MLYS

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Citigroup analyst Jeff Chung upgrades XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) from Neutral to Buy and raises the price target from $13.7 to $29.

XPEV

Citigroup Upgrades XPeng to Buy, Raises Price Target to $29

WIIM

Mineralys Therapeutics shares are trading higher after the company reported topline data from its pivotal LAUNCH-HTN Phase 3 and ADVANCE-HTN Phase 2 trials of Lorundrostat for hypertension. Both trials met the primary endpoint.

HC Wainwright &amp; Co. analyst Arthur He maintains Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) with a Buy and raises the price target from $16 to $20.

SLDB

HC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $20

Earnings

Cheer Holding Reported FY24 Revenue Of $147.2M Vs $152.3M YoY, EPS Of $2.51 Vs $3.53 YoY

TRVI

Trevi Therapeutics shares are trading higher after the company reported topline results from its Phase 2a RIVER trial of Haduvio for RCC, which met the primary endpoint.

Citigroup analyst Keith Horowitz upgrades KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) from Neutral to Buy and announces $20 price target.

Citigroup Upgrades KeyCorp to Buy, Announces $20 Price Target

RDFN

Redfin shares are trading higher after Rocket Companies announced it will acquire the company in an all-stock transaction valued at $12.50 per share.

Rocket Companies shares are trading lower after the company announced it will acquire Redfin in an all-stock transaction valued at $12.50 per share.

Novo Nordisk shares are trading lower after the company reported Phase 3 results for CagriSema, showing 15.7% weight loss over 68 weeks.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) with a Buy and maintains $6 price target.

Reiteration

ELEV

HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target

DASH

DoorDash shares are trading higher amid the company joining the S&P 500.

Barclays analyst Julian Mitchell downgrades Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) from Equal-Weight to Underweight and lowers the price target from $135 to $110.

Downgrades

Barclays Downgrades Emerson Electric to Underweight, Lowers Price Target to $110

ABNB

Airbnb shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $165 to $185.

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy and maintains $54 price target.

PTGX

HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $54 Price Target

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

IPOs

Press Releases

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Health Care

General

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

CareDx

Chimerix

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Geron

GRAIL

Gyre Therapeutics

Immunome

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Vir Biotechnology

Xencor

Zymeworks

Wedbush

HC Wainwright & Co.

Stifel

Morgan Stanley

버서스 시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>)의 주가는 회사가 <a href="https://www.benzinga.com/quote/VS/news" target="_blank" rel="noopener" data-google-interstitial="false">국제적인 입지</a>를 성장시키기 위한 전략의 일환으로 회사가 브라질 시장으로의 확장을 발표한 후 급등했다.
버서스 시스템즈의 주가가 금요일 프리마켓 거래에서 71.2% 상승하여 $3.39에 거래되었다.
금요일 프리마켓 거래에서 움직임이 있는 다른 주식들도 있다.
<h3 class="wp-block-heading">상승 종목</h3>
<ul>
<li>아이스페시맨(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>)은 hMPV 바이오스펙리멘의 공급자를 확보했다고 발표한 후 프리마켓 거래에서 49.1% 상승하여 $4.25에 거래되었다.</li>
<li>누클레우스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>)는 나스닥 상장 폐지 통지를 해결하고 상장 기준을 준수하고 있다고 발표한 후 33% 상승하여 $27.30에 거래되었다.</li>
<li>사이닝 데이 스포츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>)는 목요일에 9% 하락한 후 금요일 프리마켓 거래에서 19.2% 상승하여 $2.55에 거래되었다.</li>
<li>유클라우드링크 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>)는 WH 스미스 PLC의 인모션 엔터테인먼트 그룹(InMotion Entertainment Group)과 최근 협력 계약을 체결했다고 발표한 후 프리마켓 거래에서 18.7% 상승하여 $1.59에 거래되었다.</li>
<li>트레저 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>)는 목요일에 약 7% 상승한 후 프리마켓 거래에서 15.3% 상승하여 $0.2471에 거래되었다.</li>
<li>TXNM 에너지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>)는 프리 마켓 거래에서 14.3% 상승하여 $55.99에 거래되었다.</li>
<li>트리스 메디컬 컨셉츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>)는 2024년 4분기 및 전체 연도 매출에 대한 예비, 감사되지 않은 수치를 발표한 후 프리마켓 거래에서 14% 상승하여 $9.40에 거래되었다.</li>
<li>LSI 인더스트리즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>)는 2025 회계연도 2분기 실적을 2025년 1월 23일 목요일 시장 개장 전 발표할 것이라고 발표한 후 프리마켓 거래에서 8.8% 상승하여 $21.00에 거래되었다.</li>
<li>오소픽스 메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>)은 프리마켓 거래에서 8.1% 상승하여 $19.39에 거래되었다.</li>
</ul>
<h3 class="wp-block-heading">하락 종목</h3>
<ul>
<li>비즐리 브로드캐스트 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>)은 프리마켓 거래에서 43.8% 하락하여 $5.00에 거래되었다.</li>
<li>비아비 솔루션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>)은 프리마켓 거래에서 19.3% 하락하여 $8.10에 거래되었다. 비아비 솔루션은 2025 회계연도 2분기 재무 실적을 2025년 1월 30일 목요일 시장 종료 후 발표할 것이다.</li>
<li>FOXO 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>)는 목요일에 58% 상승한 후 금요일 프리마켓 거래에서 18.4% 하락하여 $0.2566에 거래되었다.</li>
<li>네이처스 선샤인 프로덕츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>)는 프리마켓 거래에서 15.9% 하락하여 $12.00에 거래되었다.</li>
<li>엘리시오 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>)는 프리마켓 거래에서 12.8% 하락하여 $5.61에 거래되었다.</li>
<li>G. 윌리푸드 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WILC#NASDAQ">WILC</a>)는 프리마켓 거래에서 11.5% 하락하여 $14.01에 거래되었다.</li>
<li>바이카라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>)는 목요일에 8% 하락한 후 금요일 프리마켓 거래에서 11.5% 하락하여 $10.51에 거래되었다.</li>
<li>J.B. 헌트 트랜스포트 서비스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>)는 회사가 목요일에 예상보다 낮은 4분기 실적을 발표한 후 프리마켓 거래에서 10.3% 하락하여 $167.00에 거래되었다.</li>
<li>MiMedx 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>)은 프리마켓 거래에서 6.3% 하락하여 $8.50에 거래되었다.</li>
<li>알보텍(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>)은 회사가 $500만 공모 가격을 발표한 후 프리마켓 거래에서 5% 하락하여 $12.60에 거래되었다.</li>
<li></li>
</ul>
이것도 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EA%B8%88%EC%9A%94%EC%9D%BC-%EC%A3%BC%EB%AA%A9%ED%95%B4%EC%95%BC-%ED%95%A0-%EC%A3%BC%EC%8B%9D-%ED%8C%A8%EC%8A%A4%EB%84%90-jb-%ED%97%8C%ED%8A%B8-%EC%8A%A4%ED%85%8C%EC%9D%B4%ED%8A%B8-%EC%8A%A4/" target="_blank" rel="noopener">금요일 주목해야 할 주식: 패스널, JB 헌트, 스테이트 스트리트, 코보 및 슐럼버거</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Bicara Therapeutics

뉴스

에 대한 최신 뉴스 Bicara Therapeutics (NASDAQ:BCAX) 주식

금요일, 1월 17, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌